Introduction
Recently, we showed that benzene, toluene, and chloroform induce hyperphosphorylation of the tumor-suppressor gene product p53 (1) . Hyperphosphorylation of p53 and pRb105 by promoters like 12-O-tetradecanoylphorbol-13-acetate (TPA), benzene, toluene and chloroform is probably due to their effects via protein kinase C (PKC) or by inducing a cascade effect in kinases responsible for signal transduction (1) (2) (3) (4) . Stimulation of kinase activity and the subsequent hyperphosphorylation of tumorsuppressor gene products, may partially account for the promotional effects exhibited by benzene, toluene, and chloroform. Promoter attenuation of p53's ability to induce cell cycle arrest may also keep p53 from preventing the replication of damaged DNA (5) . Therefore, posttranslational modification of p53 or other tumor-suppressor gene products induced by benzene or toluene may also be a factor in determining the relative carcinogenicity of the two solvents.
Since benzene and toluene both appear to have adverse effects on molecular mechanisms that control cell growth and prevent the duplication of genetic errors, these effects do not explain the apparent differences in the ability of the two solvents to cause cancer. It is clear that benzene is a carcinogen, but toluene is thought to be either noncarcinogenic or to have little potential to induce cancer in hematopoietic cells.
To resolve the difference in the carcinogenic potential of benzene and toluene, we examined the ability of these two solvents to induce cyclin-dependent kinase 2 (Cdk2) activity and to hyperphosphorylate pRb 1O5. Cdk2 has been previously associated with the promotional effects of estrogen and phosphorylates the tumor-suppressor gene product pRblO5 (6) . We hypothesized that differences in kinase induction and post translation modification of proteins like pRblO5 might account for the apparent differences in carcinogenicity shown by benzene and toluene. Hyperphosphorylation of pRblO5 was examined in rat liver epithelial (RLE) and HL60 cells that had been treated with benzene or toluene. Cdk2 kinase activity in cells treated with benzene and toluene was also determined.
Previous studies have also suggested that p53 DNA site-specific DNA binding is increased in cells treated with DNAdamaging agents and chemotherapeutic agents (7) . We hypothesized that the ability to damage DNA might be responsible for the apparent differences in carcinogenic potential of benzene and toluene. Therefore, we examined p53-DNA binding in RLE cells treated with toluene or benzene.
Materials and Methods
Cell lines examined in this study included WB-F344 RLE cells, which were a gift from Dr. James Trosko of Michigan State University (1) . Because RLE cells appear to produce a wild-type p53 and pRblO5 (8) , they were used for immunoprecipitation of pRblO5, Cdk2, and p53-DNA sequencespecific binding studies. Because the HL60 cells, obtained from the American Type Culture Collection, produce mutant p53 and the pRblO5 status is unknown, they were only examined for Cdk2 activation.
RLE cells were maintained in Richter's medium, and HL6O cells were maintained in RPMI 1640. Both cell lines were incubated at 37°C in a 5% CO2 atmosphere.
RLE cells were maintained with 5% (v/v) calf serum and HL60 cells in 20% fetal bovine serum. Prior to studies on Cdk2 activation, the respective serum concentrations were reduced to 0.5% (v/v) for 48 hr.
Hyperphosphorylation of pRb 105 in RLE cells was examined by adding 0 to 2% (v/v) benzene or toluene to the medium of the adherent cells similar to procedures described previously (1) . Briefly, pRblO5 was radiolabeled using [32P]-ortho-phosphoric acid and the cells were lysed (1). pRblO5 was immunoprecipitated (1) . Total protein of all extracts was determined using Environmental Health Perspectives * Vol 104, Supplement 6 * December 1996 l1289 a commercial BCA protein assay (Pierce Biochemicals, Rockford, IL). Samples were equalized on total protein before immunoprecipitations were performed. AntipRb 105 monoclonal antibody was obtained from Oncogene Sciences (Manhassett, NY). Radiolabeled cell extracts were incubated with the antibody and protein A/G agarose overnight. The agarose immune complexes were precipitated using microcentrifugation, and then the supernatants were removed and discarded. The agarose beads were washed with lysis buffer and then centrifuged. Standard denaturing gel sample buffer was added, and the immunoprecipitates examined using denaturing gel electrophoresis followed by autoradiography. Polyacrylamide gels used were 8.0% from a commercial source (Novex Inc., San Diego, CA Richter's medium supplemented with 0.5% calf serum. The medium was replaced before adding compounds for test with fresh medium without serum. Cells were then incubated for 2 hr. Untreated control cells were also examined. Nuclear extracts from the cells were prepared as described (5) . Briefly, the medium was removed from the cells, and the monolayers were washed with PBS, pH 7.4. Cells were lysed by the addition of 2.5 ml buffer (20% glycerol, 10 mM NaCl, 1.5 mM MgC12, 0.2 mM EDTA, 1 mM dithiothreitol, 1 mM PMSF, and 0.1% Triton X-100 in 20 mM HEPES buffer, pH 7.6). The lysate was centrifuged at 800g for 4 min and the resulting pellet was diluted with 3 vol of 500 mM NaCl in buffer (see above) and then incubated at 4°C for 30 min with agitation. The mixture was centrifuged at 35,000g for 10 min and the supernatants containing p53 were removed for immediate analysis. The total protein content of the extracts was determined using BCA protein assays (Pierce Biochemicals). Protein content for all samples was equalized before performing the binding assay. Cdk2 activity increases in relation to the applied dose of benzene (Figure 2a ) added to the medium of RLE or to HL60 cells (Figure 2b ). Similar dose-dependent increases in Cdk2 activity are obtained when using toluene (data not shown). Differences in the amount of Cdk2 activation may be caused by different susceptibilities of the cells to the two solvents. However, it cannot be determined if this variation is caused by some feature of the experimental methods used. Since the solvents are not fully miscible in the medium, the applied dose under these conditions is difficult to control. In addition, the solvents, especially at high doses, may also be highly toxic to the cells. Longer application of the solvents at 1 or 2% (v/v) resulted in toxic death of RLE cells.
DNA-damaging and chemotherapeutic agents increase p53-DNA site-specific binding in RLE cells ( Figure 3A) . Benzene treatment of RLE cells was found to increase p53-DNA binding when compared to control cells ( Figure 3B ). p53-DNA binding was also increased over control levels in cells treated with toluene ( Figure 3B ), but the effect was markedly less than that produced by benzene.
Increased amounts of HSP 72/73 is precipitated from benzene-and toluenetreated RLE cells using the anti-HSP72/73 antibody ( Figure 4) (6) . The xenoestrogen DDT also increases Cdk2 activity (10) . Hyperphosphorylation of pRblO5 and p53 that occurs as a result of the effects of chemical promoters on kinase activity may be an essential component of their growth-stimulating properties. Hyperphosphorylation of p53, for example, has been shown to decrease the ability of p53 to activate transcription (11) .
No outstanding differences between the ability of benzene or toluene to phosphorylate pRb105 or induce Cdk2 activation were found that might explain the difference in the carcinogenic potential of these two solvents. However, p53-sequencespecific DNA binding was found to be elevated in cells treated with 2% benzene when compared to cells treated with toluene or control cells. Increased p53 DNA sitespecific DNA binding has been demonstrated in cells treated with DNA-damaging or chemotherapeutic agents that affect DNA-manipulating enzymes (5). DNAdamaging chemicals and chemotherapeutic agents increase p53-DNA binding in RLE cells (Figure 3A) , as do high concentrations (2% v/v) of benzene ( Figure 3B ), and to a lesser extent, toluene ( Figure 3B ). Lower concentrations of toluene or benzene (1% v/v) fail to markedly increase p53-DNA binding in RLE cells ( Figure 3B ). If benzene-induced increase in p53 DNA sitespecific DNA binding can be attributed to a molecular mechanism occurring in response to DNA damage (5), benzene may be more capable of damaging genetic material. Therefore, this may account for the carcinogenicity demonstrated by benzene in relation to toluene. However, other cellular stresses including hypoxia have also been shown to increase p53-DNA binding, but the increased p53 levels are thought to occur by a different mechanism than radiation-induced DNA damage (12) . The tumor promoter okadiac acid, an inhibitor of protein phosphatases, has been shown to also increase the steady-state level of p53 without altering p53-DNA binding (13) . Heat shock has been shown to increase the intracellular levels of p53, which is bound by heat shock protein (14) . Therefore, cellular effects by benzene that result in stress may be responsible for the increase we see in p53-DNA binding. Increased levels of HSP were precipitated from benzene-and toluene-treated cells (Figure 4) . However, no evidence of coprecipitation of p53 by anti-HSP or precipitation of HSP by anti-p53 could be found. Therefore, we cannot attribute the change in p53-DNA binding in solvent-treated cells to HSP, nor can we rule it out. Whatever cellular stress is indicated by increased p53-DNA binding after treatment of benzene that is not evident with toluene, it still may represent a central difference between the two solvents that is directly related to carcinogenicity. Further studies will be required to determine if benzene-induced p53-DNA binding is directly related to DNA damage or is caused by some other form of cellular stress.
